Search

Your search keyword '"Michela Cangemi"' showing total 2 results
Start Over Author "Michela Cangemi" Publication Type Magazines
2 results on '"Michela Cangemi"'

1. High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab

Author

Cox, M. Christina Christina, Rozera, Carmela, Mattei, Mauro, Muraro, Elena, Aricò, Eleonora, Di Napoli, Arianna, Pavan, Antonio, Di Landro, Francesca, Santodonato, Laura, Martorelli, Debora, D'Agostino, Giuseppina, Lapenta, Caterina, Hohaus, Stefan, Cuccaro, Annarosa, Cantonetti, Maria, Zoli, Valerio, Berdini, Cinzia, Sonia, Borgioni, Pupo, Livio, Prosperi, Daniela, Donati, Simona, Napolitano, Mariarosaria, Michela, Cangemi, Montefiore, Enrica, Carlei, Davide, Monque, Domenica, Ruco, Luigi, Tafuri, Agostino, Dolcetti, Riccardo, Santini, Stefano Maria, Capone, Imerio, and Belardelli, Filippo

Abstract

No relevant conflicts of interest to declare.

Published
2018
Full Text
View/download PDF

2. High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab

Author

Cox, M. Christina Christina, Rozera, Carmela, Mattei, Mauro, Muraro, Elena, Aricò, Eleonora, Di Napoli, Arianna, Pavan, Antonio, Di Landro, Francesca, Santodonato, Laura, Martorelli, Debora, D'Agostino, Giuseppina, Lapenta, Caterina, Hohaus, Stefan, Cuccaro, Annarosa, Cantonetti, Maria, Zoli, Valerio, Berdini, Cinzia, Sonia, Borgioni, Pupo, Livio, Prosperi, Daniela, Donati, Simona, Napolitano, Mariarosaria, Michela, Cangemi, Montefiore, Enrica, Carlei, Davide, Monque, Domenica, Ruco, Luigi, Tafuri, Agostino, Dolcetti, Riccardo, Santini, Stefano Maria, Capone, Imerio, and Belardelli, Filippo

Abstract

Purpose:We havedeveloped a novel DC population differentiated from human monocytes in the presence of GM-CSF and IFN-alpha (IFN-DC), which is highly efficient in internalizing tumour cell antigens and in the cross-priming of CD8+T cells, promoting efficient anti-lymphoma response. Preclinical results prompted us to start a clinical trial of IFN-DC combined with low-dose Rituximab(RTX) in patients with Follicular lymphoma (FL), which is an indolent, immune-responsive, but still incurable cancer.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results